ADDY ALT-HOLLAND, PhD., Assistant Professor, Department of Endodontics, Tufts University School of Dental Medicine
JAMES D. BALEJA, Ph.D., Associate Professor, Department of Developmental, Molecular, and Chemical Biology, Tufts University School of Medicine.
DANIEL OREADI, D.M.D. Assistant Professor, Department of Oral and Maxillofacial Surgery, Tufts University School of Dental Medicine and Tufts Medical Center
BICHCHAU MICHELLE NGUYEN, M.D., MPH, Assistant Professor of Dermatology, Director, Mohs Micrographic Surgery, Tufts University School of Medicine, Tufts Medical Center
SUZANNE OLBRICHT, M.D., Chair, Chief of Dermatology; Rachel Reynolds, MD-Vice Chair; Beth Israel Deaconess Medical Center
Basal cell carcinoma nevoid syndrome (BCCNS) is characterized in part by numerous basal cell carcinoma (BCCs) tumors forming with increasing frequency through life, multiple keratocystic odontogenic tumors (KCOTs), and skeletal, ophthamic, and neurological abnormalities. Initially described in 1960 by Drs. Robert Gorlin, a dentist, and Robert Goltz, a dermatologist, BCCNS is often first diagnosed by the development and presentation of KCOTs in the jaw of affected individuals. These tumors have a marked tendency to recur and can cause a host of serious dental complications, including displacement and loss of developing permanent teeth, malocclusion, and local destruction of jaw bones.
KCOTs are often first recognized by dentists during adolescence and in some cases within the first decade of a patient's life. Early detection of these cancerous lesions and other BCCNS symptoms is of the utmost importance for early intervention, as rigorous management of both KCOTs and BCCs is necessary in this patient population. Treatment modalities for the different manifestations of the syndrome vary widely from conservative to aggressive, and require a collaborative and communicative interprofessional approach.
This course will offer a unique opportunity for dentists, dermatologists, and scientists to meet BCCNS patients, and to interact with, listen to, and learn from each other in a supportive, academic environment of TUSDM. Illustrating to clinicians the complexity of diagnosing BCCNS, this course will provide an overview of the clinical appearance and treatment modalities of KCOTs and BCC tumors, as well as an introduction to the development of new clinical research studies and novel diagnostic approaches for BCCNS patients.
Supported by Dean Huw Thomas this program is part of the 150th Anniversary Celebration events at TUSDM and an integral component of the 2018 BCCNS Boston Regional Meeting. Hosted at TUSDM and organized by Dr. Addy Alt-Holland and the BCCNS Alliance, the only patient advocacy organization in the U.S. dedicated to this syndrome, this is a one-in-a-kind event for BCCNS patients, their families and medical professionals.
'Clinical Research study of epidermal metabolic diagnostics in BCCNS patients' by Addy Alt-Holland, PhD
'Epidermal diagnostics of inner health' by James Baleja, PhD
'The biology, diagnosis and management of KCOTs' by Daniel Oreadi, DMD
'An overview of the biology and diagnosis of skin BCC tumors' by Suzanne Olbricht, MD
'Dermatological procedural interventions for BCCNS' by Bichchau Michelle Nguyen, MD
*If you are an individual with BCCNS or a family member who would like to attend this event, please register at the BCCNS Alliance page
Lecture: Credit Hours - 3
AGD Code: 730
This course is free